Observational Study on Energy Expenditure and Protein Metabolism Changes in Patients With Severe Brain Injury.
1 other identifier
observational
6
1 country
1
Brief Summary
Evaluation of early energy metabolism and muscle mass changes in patients with severe brain injury, the impact of nutritional therapy on metabolism and muscle mass, and their relationship with patient prognosis, to provide clinical research references for the implementation of individualized nutritional therapy in patients with severe brain injury.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Apr 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 15, 2024
CompletedFirst Submitted
Initial submission to the registry
August 27, 2024
CompletedFirst Posted
Study publicly available on registry
August 29, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
April 15, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
December 15, 2025
CompletedAugust 29, 2024
August 1, 2024
1 year
August 27, 2024
August 27, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Basal Metabolic Rate
first 10 day
Interventions
nutritional support
Eligibility Criteria
patients with critical neurological illness
You may qualify if:
- Patients with severe neurological critical illness admitted to the ICU, including moderate to severe acute cerebrovascular disease, severe acute craniocerebral injury and spinal cord injury, central nervous system bacterial infections, status epilepticus, neurosurgical patients requiring life support during the perioperative period, and other progressive severe neurological conditions.
- Age ≥ 18 years old.
- Receiving invasive mechanical ventilation.
- Willing to sign an informed consent form.
You may not qualify if:
- Women of childbearing age with a positive pregnancy test, pregnant, or lactating women.
- Chronic diseases with severe organ dysfunction or serious complications:
- Heart: New York Heart Association (NYHA) Functional Classification IV.
- Lung: Chronic respiratory failure requiring long-term oxygen therapy.
- Kidney: Chronic kidney disease stage 4 or 5; Liver: History of liver failure, hepatic encephalopathy, or hepatic coma, recent gastrointestinal bleeding due to portal hypertension, or Child-Pugh score ≥ 10.
- Cancer patients with cachexia, or with severe organ dysfunction due to obstruction, mass effect, compression, or those who have not undergone surgery due to difficulty or recent chemotherapy or immunotherapy within one month.
- Severe immunodeficiency or current use of potent immunosuppressants, agranulocytosis (N \< 0.5×10\^9/L), active hematologic malignancy, or HIV infection stage III; currently undergoing immunosuppressive induction therapy, such as antithymocyte globulin (ATG), antilymphocyte globulin (ALG), interleukin 2 receptor alpha chain antibody (IL-2RA), interleukin 6 receptor A antibody (IL-6RA), etc.; continuous use of glucocorticoids for more than 2 weeks, with a daily dose exceeding the equivalent of 200 mg of hydrocortisone.
- Acute gastrointestinal injury (AGI) grade IV, such as intestinal ischemia and necrosis, gastrointestinal bleeding leading to hemorrhagic shock, abdominal compartment syndrome (IAP \> 20mmHg) requiring active decompression, etc.
- Implanted with life-sustaining devices such as a pacemaker.
- In a critical condition with an expected survival time of less than 24 hours.
- Receiving or requiring dialysis or renal replacement therapy within 6 hours (this time frame is considered to exclude patients who may have acute changes in renal function that could confound the study outcomes or who may be in a transient state that could resolve without the need for long-term dialysis or renal replacement therapy).
- Patients requiring or currently receiving extracorporeal membrane oxygenation (ECMO) treatment.
- Combined with severe and above burns: total body surface area of burns exceeding 30% or III-degree burns area exceeding 10%; or with a total area of less than 30%, but with a severe overall condition or in shock, combined injuries, or respiratory tract burns.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Zhongda Hospital, Southeast university
Nanjing, Jiangsu, China
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 30 Days
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Attending Physician
Study Record Dates
First Submitted
August 27, 2024
First Posted
August 29, 2024
Study Start
April 15, 2024
Primary Completion
April 15, 2025
Study Completion
December 15, 2025
Last Updated
August 29, 2024
Record last verified: 2024-08